


Gross et al., "Antitumor Activity of the Glutaminase Inhibitor CB-839 in TNBC"
Supplementary Figure S4



Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines. A, phosphate-activated glutaminase specific activity (log₂ transformed) measured in lysates from TNBC and receptor-positive breast cancer cell lines. B, extent of cell proliferation or cell loss following treatment of TNBC and receptor-positive breast cancer cell lines with 1 μ M CB-839 for 72 hours. C, extent of cell proliferation or cell loss for TNBC and receptor-positive breast cancer cell lines deprived of extracellular glutamine for 72 hours. D, baseline ratio of glutamate to glutamine (log₂ transformed) in TNBC and receptor-positive breast cancer cell lines. E, fold increase in intracellular glutamine (log₂ transformed) in TNBC and receptor-positive breast cancer cell lines treated with 1 μ M CB-839 for 4 hours. F, fold decrease in intracellular glutamate (log₂ transformed) in TNBC and receptor-positive breast cancer cell lines treated with 1 μ M CB-839 for 4 hours. Each datapoint represents one cell line; the horizontal bars denote the mean (large bar) and SD (smaller bars) for the two populations. Statistical analyses were performed by unpaired t-test: ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.